€102m NIB loan finances Elekta’s R&D activities for cancer care

In:

Social infrastructure

Region:

Europe

The Nordic Investment Bank and the Swedish medical equipment solutions provider Elekta AB have signed a €102 million, seven-year loan to finance R&D costs for the development of new radiotherapy solutions.

Elekta’s research programme for 2021–2025 focuses on the development of radiation therapy and radiosurgery tools, clinical treatment solutions and workflow-enhancing software systems.

Stockholm-headquartered Elekta’s R&D efforts aim to integrate interdisciplinary activities and support cooperation with clinics and academic hospitals. This intends to improve control of radiation physics, radiation dose calculation, software development and deep learning.

View source

Video

11 June 2026

COFIDES steps ahead: Catalysing private capital, originating...

Ángela Pérez, CEO and chair at COFIDES, spoke to Uxolo at the lill Global Symposium 2026 in Oxford. Here she talks risk-sharing and catalysing private capital in the...

Life sciences: DFIs test a new frontier in health PPP

Perspective

11 June 2026

Life sciences: DFIs test a new frontier in health PPP

Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even...

Must See

Green Sky SAF: An Egypt first with lending precedents

Perspective

04 June 2026

Green Sky SAF: An Egypt first with lending precedents

A landmark sustainable aviation fuel project in Egypt shows that commercial banks and local equity can get behind emerging transportation fuels. But shared experience on an earlier SAF financing helped assure a painless close.

Video

11 June 2026

COFIDES steps ahead: Catalysing private capital, originating deals, and learning to measure impact

Ángela Pérez, CEO and chair at COFIDES, spoke to Uxolo at the lill Global Symposium 2026 in Oxford. Here she talks risk-sharing and catalysing private capital in the development finance industry.

Perspective

11 June 2026

Life sciences: DFIs test a new frontier in health PPP

Biovac’s EU-backed quasi-equity package and Brazil’s planned $1.2 billion vaccine PPP suggest that life-sciences are increasingly viewed as social infrastructure. But even vaccine sovereignty is hard to bank without public risk-sharing, demand visibility and unusually credible developers.